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Fibronectin (FN) deposition mediated by fibroblasts is an
important process in matrix remodeling and wound healing.
By monitoring the deposition of soluble biotinylated FN, we
show that the stress-induced TG-FN matrix, a matrix complex
of tissue transglutaminase (TG2) with its high affinity binding
partner FN, can increase both exogenous and cellular FN de-
position and also restore it when cell adhesion is interrupted
via the presence of RGD-containing peptides. This mecha-
nism does not require the transamidase activity of TG2 but
is activated through an RGD-independent adhesion process
requiring a heterocomplex of TG2 and FN and is mediated
by a syndecan-4 and 1 integrin co-signaling pathway. By
using 5 null cells, 1 integrin functional blocking anti-
body, and a 51 integrin targeting peptide A5-1, we dem-
onstrate that the 5 and 1 integrins are essential for
TG-FN to compensate RGD-induced loss of cell adhesion
and FN deposition. The importance of syndecan-2 in this
process was shown using targeting siRNAs, which abolished
the compensation effect of TG-FN on the RGD-induced loss
of cell adhesion, resulting in disruption of actin skeleton
formation and FN deposition. Unlike syndecan-4, synde-
can-2 does not interact directly with TG2 but acts as a
downstream effector in regulating actin cytoskeleton orga-
nization through the ROCK pathway. We demonstrate that
PKC is likely to be the important link between syndecan-4
and syndecan-2 signaling and that TG2 is the functional
component of the TG-FN heterocomplex in mediating cell
adhesion via its direct interaction with heparan sulfate
chains.
Fibronectin (FN)3 mediates the cell adhesion process by
interacting with cell surface receptors through its different
cell binding sites. It is essential to embryogenesis and found
associated with the extracellular matrix in large quantities
during wound healing and angiogenesis. The amino acid se-
quence Arg-Gly-Asp (RGD) found within FN and many other
matrix proteins is the most widely occurring cell-adhesive
motif (1). It is the most important recognition site for about
half of all known integrins, such as 51, V1, V3, and
V5 (2). However, this cell adhesion process can easily be
inhibited by the presence of competitive peptides containing
the RGD sequence, often leading to apoptosis (anoikis) (3, 4).
Such peptides are commonly released during matrix remodel-
ing, a process that is essential to both wound healing and an-
giogenesis (5–7). Of the integrins, 51 integrin is probably
the major cell surface integrin that interacts with the RGD-
cell binding site on FN, initiating the cell adhesion process (8),
whereas the binding of v3 integrin to the RGD domain can
also support cell adhesion on FN (9). In addition to the RGD-
cell binding domains, the heparin binding sites within FN
have also been reported to be involved in cell adhesion be-
cause, although cell binding to the RGD-cell binding domains
of FN can initiate the cell adhesion process, it is not sufficient
to fully support actin cytoskeleton formation, an observation
that led to the discovery of the cell surface heparan sulfate
proteoglycan syndecan-4 (10, 11). Syndecan-4 is the most
ubiquitous member of a larger syndecan family that interacts
with the heparin binding domains of FN and supports the
formation of a cytoskeletal network (12, 13). A further role of
another syndecan family member, syndecan-2, was demon-
strated as a downstream molecule in the syndecan-4 signaling
pathway (14), although the intermediate protein(s) mediating
this signaling have not been characterized. Apart from sup-
porting the cell adhesion process, cell surface receptors are
also involved in the assembly of inactive soluble fibronectin
dimers into insoluble fibronectin fibrils to further support the
cell adhesion process, among which 51 integrins are proba-
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bly the most efficient regulators and the most widely studied
(15). Cell contractility mediated via the actin-myosin cy-
toskeleton and stimulated via activation of GTPase Rho (16) is
needed to stretch the soluble fibronectin dimers, making the
cell surface receptor binding sites available.
A further cell surface protein also implicated in cell adhe-
sion and matrix deposition is the enzyme tissue transglutami-
nase (TG2). This Ca2-dependent enzyme catalyzes the
post-translational modification of proteins either via their
cross-linking through  (-glutamyl) lysine bridges or by the
incorporation of primary amines (17). Although mainly found
intracellularly, during stress/injury situations, TG2 is up-reg-
ulated and secreted into the extracellular space by an unchar-
acterized mechanism, which requires an active site conforma-
tion (18) and may involve binding to cell surface FN and
heparan sulfate proteoglycans (19, 20). When present at the
cell surface and in the extracellular matrix, TG2 is tightly as-
sociated with fibronectin, for which it has a high affinity (19).
In our previous work, we demonstrated that formation of the
TG-FN heterocomplex can modulate cell behavior, including
cell adhesion and spreading and their relevant signal trans-
duction pathways (7, 18, 21). We demonstrated that the
TG-FN heterocomplex can compensate for the RGD peptide-
induced loss of cell adhesion through a syndecan-4 and 1
integrin co-signaling pathway supporting both cell adhesion
and cell survival (22). We illustrated how this mechanism
could be physiologically important by showing that a TG2-
rich conditioned matrix produced by TG2-transfected Swiss
3T3 cells could also compensate for RGD peptide-induced
loss of cell adhesion (22). We also illustrated how this com-
pensation mechanism is particularly important for cell sur-
vival during situations involving matrix remodeling (e.g.
wounding and scarring, angiogenesis, and tumor metastasis),
where high levels of TG2 and RGD peptides are released dur-
ing the matrix remodeling process (23–25).
In this paper, we have extended this work to explore the
involvement of the RGD-independent adhesion mediated by
TG-FN matrix in fibronectin matrix assembly, an event cen-
tral to matrix remodeling and key to the process of many
physiological and pathological situations where TG2 is found
(26). We also explore the involvement of other cell surface
receptors in addition to 1 integrin and syndecan-4, including
syndecan-2 and 5, 4, and 3 integrins, in this process. Our
findings suggest that cell spreading mediated by the TG-FN
heterocomplex can lead to fibronectin matrix assembly even
in the presence of RGD-containing peptides by a process in-
volving cross-talk between the cell surface receptors synde-
can-4, syndecan-2, and 51 integrin linked by the intracellu-
lar signaling molecule PKC.
EMPERIMENTAL PROCEDURES
Reagents and Antibodies—Human plasma fibronectin was
purchased from Sigma-Aldrich or Calbiochem. The FN syn-
thetic peptides GRGDTP, GRADSP, and Rho kinase (ROCK)
inhibitor Y27632 were from Calbiochem. Sulfo-NHS-LC-Bio-
tin was obtained from Pierce. The GK21 peptide (GENPIYK-
SAVTTVVNPIYEGK) and the scrambled control peptide
(GTAKINEPYSVTVPYGEKNKV) in tandem with the anten-
napedia third helix sequence (PQIKIWFQNRRMKWKK) and
the A5-1 peptide (VILVLF) were chemically synthesized by
Peptide Protein Research. Anti-TG2 antibody CUB7402 was
from Neomarkers. The rabbit anti-5 integrin, rabbit anti-1
integrin, mouse anti-human FAK, and mouse anti-PKC were
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); the
anti-mouse 3 integrin antibody was purchased from Pharm-
ingen; the mouse anti--tubulin antibody, mouse anti-cellular
FN antibody, and mouse anti-vinculin antibody were from
Sigma-Aldrich; and anti-human Tyr(P)397 and Tyr(P)861 were
from Upstate Cell Signaling Solutions and BIOSOURCE, re-
spectively. The Armenian hamster anti-1 integrin antibody
(HM1-1) and its IgG isotype control antibody and rat anti-
mouse integrin 4 antibody and its rat IgG isotype control
antibody were obtained from Biolegend. The rabbit polyclonal
anti-syndecan-4 and syndecan-2 antibodies, which recognize
the intracellular domains in the core proteins of these recep-
tors, were from Zymed Laboratories Inc. Invitrogen. CyTM5-
conjugated streptavidin was from Jackson ImmunoResearch.
The rabbit polyclonal anti-phosphotyrosine antibody was
purchased from BD Biosciences. Vectashield mounting me-
dium was purchased from Vector Laboratories. Purified
guinea pig liver TG2 (gplTG) was purified according to Leb-
lanc et al. (27). The site-directed irreversible transglutaminase
inhibitor 1,3-dimethyl-2-imidazolium derivative R283 (28)
was synthesized at Aston University. Specific siRNAs target-
ing mouse syndecan-2 and the universal negative control
siRNA were purchased from Qiagen, whereas the scrambled
siRNAs were synthesized by Sigma-Aldrich.
Cell Lines—EA5, EA5/5, 3 wild type, and 3 null MEF
cells were cultured according to Huveneers et al. (15). Wild
type T98G glioblastoma cells and transfected T98G cells with
syndecan-2 or syndecan-4 vectors were grown as reported
previously (29). Wild type, syndecan-4 null, and 1 integrin
null mouse embryo fibroblast (MEF) cells were grown as de-
scribed previously (22). Parental Chinese hamster ovary
(CHO) and CHO-K1 cells were purchased from ATCC and
grown in Ham’s F-12 medium according to the supplier’s
instructions.
Establishment of the TG2-transfected MEF (tg2-MEF) Cell
Line—Transfection Of wild type MEF cells with the pSV40/
Zeo2 expression vector containing wild TG2 cDNA was
achieved by transfecting cells with the 5 g of vector using a
Nucleofector system (AMAXA Biosystems) according to the
manufacturer’s protocol. Clones resistant to 800 g/ml Zeo-
cin (Geneticin, Calbiochem) were screened for overexpression
of TG2 by Western blotting as described below.
Cell Adhesion Assay—Cell adhesion assays were performed
as described previously (7, 22). Unless otherwise stated, cells
were detached with 0.25% (w/v) trypsin, and the trypsin was
neutralized either with trypsin inhibitor or by the addition of
serum-containing medium. Following serum starvation for
16 h, cells were detached as described above and then washed
three times with serum-free medium to remove any traces of
serum or trypsin inhibitor and pretreated with GRGDTP pep-
tide or its control peptide GRADSP in serum-free medium for
20 min. Based on previous toxicity findings (7, 22), adhesion
experiments were performed using 100 g/ml RGD synthetic
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peptide, leading to partial inhibition in cell adhesion. Cells
were then seeded onto 96-well plates (2.5 104/well) coated
with human plasma FN (FN matrix) with or without immobi-
lized guinea pig liver TG (gplTG) (TG-FN matrix) as de-
scribed previously (7, 22). Briefly, the TG-FN matrix was pre-
pared by incubating 20 g/ml gplTG in a 96-well plate
precoated with 5 g/ml FN as optimized previously (7, 22). In
order to block the heparin binding sites within FN (30) or
TG2 molecules (31), 300 g/ml heparin in 50 mM Tris-HCl,
pH 7.4, was used before and after the immobilization of
gplTG as described previously (22). In certain experiments,
the cells were pretreated with specific antibodies, inhibitors,
or peptides for 30 min to 1 h. For inhibition of 4 integrin-
mediated cell adhesion, cells were pretreated with anti-4
integrin antibody 9C10 for 1 h in the presence of a 100 g/ml
concentration of either GRADSP or GRGDTP peptide. In
order to block the cell adhesion process mediated by 1 inte-
grins, cells were pretreated with 25 g/ml HM1-1 for 1 h.
For the ROCK inhibition experiment, cells were pretreated
with the specific ROCK inhibitor Y27632 (10 M) for 30 min
(32). GK21 peptide (which blocks the interaction between
PKC and 1 integrin at the cytoplasmic domain) (22) or
A5-1 peptide (which binds to and inactivates 51 integrin)
(33) was used for incubations with MEF cells for 30 min, and
the treated cells were used in cell adhesion assays.
Cells were allowed to attach for 20–40 min to minimize
the secretion of any endogenous proteins. Cells were fixed,
permeabilized, and stained, and digital images per each sam-
ple were acquired as stated before (7, 22). Cell attachment and
spreading were quantified, and the number of cells per image
was assessed as described previously (22).
siRNA Transfection—The siRNA solutions were prepared
according to the manufacturer’s instructions and stored at
20 °C. Before transfection, 3 105 cells were seeded into
each well of a 6-well plate for 24 h to reach 50–80% conflu-
ence. 150 ng of siRNAs were used for each transfection as
directed by the manufacturer. Following an approximately
30-h siRNA transfection, cells were used inWestern blotting or
cell adhesion assay. To visualize the presence of syndecan-2 in
the syndecan-2 siRNA-treatedMEF cells, the treated cells were
seeded into 8-well chambers and incubated with rabbit anti-syn-
decan-2 antibody (recognizing the intracellular domain of the
syndecan-2 core protein) and FITC-conjugated anti-rabbit sec-
ondary antibody after fixation and permeabilization. The nuclei
were detected with propidium iodide, and the signals were de-
tected via confocal microscopy. The sequences of the siRNAs
were as follows: SDC-2 siRNA 1, TGGAATTTAATTTGTA-
GAATA; SDC-2 siRNA 2, CAAAGGCAAATTAATGTGTAA;
scrambled siRNA1, GTAAATTATGTAAGTTAGTAT; scram-
bled siRNA2, GATAATCAAAGCGAAATGTAT.
Analysis of FNMatrix Assembly via Fluorescence Staining—
Fibronectin fibril formation was measured by the assembly of
exogenously added biotin-labeled FN by a modification of
Huveneers et al. (15). 6 104 cells/well of wild type, synde-
can-4 null, 1 integrin null, EA5, and EA5/5 cells were
seeded onto FN or TG-FN in 8-well glass chamber slides. In
some experiments, the cells were pretreated with RAD or
RGD peptide as described above in the presence or absence of
1 mg/ml heparin. The cells were incubated for 1 h in serum-
free medium, and following washing of the adherent cells with
serum-free medium, the cells were incubated with 50 nM ex-
ogenous biotinylated FN (prepared according to the manufac-
turer’s protocol) in serum-free medium. After a specified in-
cubation period(s) (1, 3, 6, or 16 h), fixed cells were blocked
with 3% bovine serum albumin (BSA) in PBS, pH 7.4 (BSA
blocking buffer), and the cell matrices were stained with 1
g/ml Cy5-streptavidin. Slides were mounted with Vectash-
ield mountant (Vector Laboratories) and examined by confo-
cal fluorescent microscopy (Leica Lasertechnik). To detect the
deposition of the biotin-labeled FN via Western blotting, 6
105 cells (with or without the syndecan-2 siRNA treatment)
were seeded onto FN- or TG-FN-precoated 6-well plates. Af-
ter a certain time course, cell lysates containing both cells and
the deposited matrices were scraped into cell lysis buffer (22)
Equal amounts of protein from each sample (20 g) were sep-
arated by SDS-PAGE, and after Western blotting, the biotin-
labeled FN was detected by extravidin-peroxidase. The mem-
branes were reprobed for -tubulin. The amount of deposited
fibronectin was quantified by densitometry and normalized to
-tubulin and used as a measure of fibronectin deposited/cell.
Detection of the Presence of Fibrillar Cellular FN or FN-
bound TG2—Wild type MEF cells were detached and washed
twice with serum-free medium as described above. Cell sus-
pension with different cell densities (5,000, 1 104, or 2
104 cells/well) were prepared in serum-free medium in the
presence of the RGD or RAD peptides and allowed to adhere
on FN or TG-FN matrices for 3 h in 96-well plates. After in-
cubation, the cells were detached with 5 mM EDTA in PBS,
pH 7.4, and the remaining matrices were washed three times
with PBS, pH 7.4, and blocked with BSA blocking buffer for
30 min at room temperature. Anti-mouse cellular FN mono-
clonal antibody and FITC-conjugated anti-mouse secondary
antibody were used to detect the presence of deposited cellu-
lar FN. To visualize the cellular FN fibril formation, immuno-
fluorescence staining was performed by using anti-mouse cel-
lular FN antibody after seeding the cells on FN or TG-FN
matrix in the presence of the RGD or RAD peptides for 3 h.
Confocal microscopy was performed to detect the signals.
Matrix-bound TG2 was detected after incubating the cells
with FN or TG-FN matrices for 16 h after detaching the cells
with 5 mM EDTA in PBS, pH 7.4. A modified ELISA (7) was
used to measure the TG2 signal by using anti-TG2 antibody
Cub7402 and anti-mouse secondary antibody. Development
of the reaction was performed by the addition of OPD solu-
tion (Sigma-Aldrich). The color development was terminated
by the addition of 50 l of 2.5 M H2SO4, and the absorbance
was read at 450 nm using a Spectrafluor plate reader. Results
were expressed as absorbance at 450 nm.
Fluorescence Staining—Subconfluent MEF cells were se-
rum-starved for 16 h, harvested, and pretreated with 100
g/ml GRADSP or GRGDTP peptides as described above.
Cells were seeded in 8-well glass chamber slides (8 104
cells/well) previously coated with FN or TG-FN and allowed
to attach and spread for 20–40 min. Cells were fixed and per-
meabilized as described previously (7) and then blocked with
BSA blocking buffer for 30 min. For the actin stress fiber
TG-FN in Syndecan and Integrin Co-signaling and FNDeposition
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staining, the cells were incubated with FITC-labeled phalloi-
din (20 g/ml) in blocking buffer. For the focal contact stain-
ing in MEF cells, after treatment with blocking buffer, the
cells were incubated with anti-vinculin antibody (1:100 dilu-
tion) followed by anti-mouse IgG-FITC. For the syndecan-2
staining, the cells were seeded into 8-well chambers, and after
fixation and permeabilization, the wells were blocked with
BSA blocking buffer for 30 min at room temperature and
then incubated with anti-syndecan-2 antibody at 37 °C for
2 h and with FITC-conjugated anti-rabbit secondary anti-
body at 37 °C for 2 h. Slides were mounted with Vectash-
ield mountant (Vector Laboratories) and examined as men-
tioned above.
Western Blotting and Co-immunoprecipitation—Biotinyla-
tion of cell surface protein with EZ-link Sulfo-NHS-Biotin
(Sigma) was performed according to the manufacturer’s pro-
tocol. As described above, after a certain treatment, cells were
collected and lysed by the addition of 70 l of solubilization
buffer (Santa Cruz Biotechnology, Inc.). Following a preclear-
ing procedure by centrifuging at 300 g for 10 min, the sam-
ples were stored at70 °C until use. Western blotting was
performed as described previously (7). For the co-immuno-
precipitation, cells seeded onto heparin-treated TG-FN or
non-treated FN matrices were collected in lysis buffer as de-
scribed previously (22). According to the target protein and
antibody selected, either protein A- or G-Sepharose beads
and negative control antibodies were used to preclear the cell
lysates. The immunocomplexes were obtained via incubating
the precleared samples with protein A or G beads and rele-
vant specific antibody against the target protein and collected
in 30 l of Laemmli buffer. The immunoprecipitated proteins
were detected via Western blotting by using their specific
antibodies.
Statistics—Data are expressed as mean S.D. The data
shown were derived from one representative experiment (n
3) undertaken in triplicate. The comparisons between the
data sets were performed using Student’s t test (two-tailed
distribution with equal variance). Statistically significant dif-
ference between data sets was defined as by p 0.05
(two-sided).
RESULTS
RGD-independent TG-FN-mediated Cell Adhesion Can
Influence FN Deposition, but This Role Is Independent of
the Role of Cell Surface TG2 as an Integrin Co-receptor for
Fibronectin—We first investigated whether TG-FN-mediated
cell adhesion can influence FN fibril formation in both the
presence and absence of RGD peptides, given the potential
importance of this adhesion mechanism in matrix remodel-
ing. A prerequisite for fibronectin fibril formation is the for-
mation of focal adhesions (15). We therefore investigated fo-
cal adhesion formation in MEF cells treated with RAD or
RGD peptides when plated on FN or TG-FN matrices. Immu-
nofluorescence staining of vinculin shown in Fig. 1A demon-
strates that cells could not form focal adhesions when plated
on FN alone in the presence of the RGD peptides when com-
pared with the non-treated cells on FN and the cells seeded
on TG-FN. Once seeded on TG-FN, this matrix restores the
formation of focal adhesions even in the RGD peptide-treated
MEF cells, which is in keeping with our earlier findings for the
activation of GTPase RhoA in this event (7). Moreover, the
focal adhesions present in cells plated on the FN-TG seemed
much sharper compared with those plated on FN alone (Fig.
1A) when measured 40 min after plating.
We next investigated the ability of TG-FN to facilitate cell
FN fibril formation and deposition in the presence and ab-
sence of RGD peptides. First, in the presence of the RGD and
RAD control peptides, wild type MEF cells were seeded on FN
or TG-FN matrices with the addition of soluble exogenous
biotin-labeled FN and incubated for 1, 3, and 6 h. In the RAD-
treated cells seeded on TG-FN, after 1 h of incubation, FN
fibril formation could be observed, and within 6 h, extended
fibrils were easily detectable (Fig. 1B). In contrast, the same
process appeared much slower in the cells plated on FN alone
although equal numbers of cells were adhered (see Fig. 3A).
Importantly, when biotinylated fibronectin was added to
plates without cells, no fibril formation occurred (data not
shown), confirming the need for cells in this process (34).
Western blotting of the assembled biotinylated fibronectin
confirmed this increase in fibril formation in the cells plated
on FN-TG during a 1-, 3-, and 6-h time course (Fig. 1C). This
increase in fibril formation became less apparent at 6 h, sug-
gesting that TG-FN enhances the FN deposition at the early
stage of FN fibril formation. After the longer incubation time
of 16 h, the fluorescent images showed little difference (see
Fig. 3A), suggesting that matrix deposition was reaching com-
pletion. Importantly, the localization of little biotin-labeled
FN in the RGD-treated cells on FN, where both cell adhesion
and focal adhesion formation was reduced (Figs. 1A and 3A),
indicated a reduction in fibronectin fibril formation, an obser-
vation consistent with previous reports (35). This delayed
deposition of fibronectin by the RGD peptide treatment was,
however, compensated for by the TG-FN complex (Fig. 1B),
which is in keeping with the maintenance of cell adhesion, the
formation of sharp focal adhesions (Fig. 1A), and the activa-
tion of RhoA (16).
We next investigated whether FN fibril formation mediated
by TG-FN required transamidating activity by using the site-
directed irreversible TG inhibitor R283 of TG2, which selec-
tively acetonylates the active site cysteine (28), to block the
transamidating activity. As shown in Fig. 1D, no difference
was observed in the R283-treated and control cells, suggesting
that when present within the TG-FN complex, TG2 functions
as a matrix protein instead of a transamidating enzyme (7).
Considering that there are two major sources of globular
FN present in any physiological system, the extracellular FN
from serum, which is both in solution and surface-bound, and
the cellular secreted FN from fibroblasts, we undertook to
investigate the effect of TG-FN matrix on cellular FN deposi-
tion. The deposition of cellular FN was detected by using an
anti-mouse cellular FN antibody, which only recognizes the
deposited FN of cellular origin. The quantitative assay was
based on detecting the deposited FN by ELISA after removal
of cells by 5 mM EDTA in PBS, which can detach the cells
without disrupting the matrix (Fig. 2A). Detection of the de-
posited FN was also detected by immunofluorescence (Fig.
TG-FN in Syndecan and Integrin Co-signaling and FNDeposition
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2B). The assay was undertaken on cells seeded on FN or
TG-FN in the presence of RGD or RAD peptides after 3 h of
incubation. As shown in Fig. 2, A and B, the RGD peptides not
only blocked the exogenous FN deposition (see Fig. 1, B and
C) but also inhibited the deposition of the cellular FN, which
could be compensated for by the seeding of the cells on the
TG-FN matrix.
One question that aroused our interest is whether the TG2
in the TG-FN matrix complex can still be available to the cells
after the formation of the newly deposited FN matrix. Hence,
FIGURE 1. TG-FN promotes RGD-independent deposition of exogenous fibronectin. A, WT MEF cells treated with RAD or RGD peptide was seeded on
FN or TG-FN matrix. After a 1-h incubation, focal contacts were visualized via fluorescence staining of vinculin. B, biotin-labeled FN was applied to the
monolayer of WT MEF cells on FN or TG-FN matrix in the presence of RAD or RGD peptide. Following 1-, 3-, and 6-h incubation, biotinylated FN was de-
tected via fluorescence staining, as described under “Experimental Procedures.” C, biotin-labeled FN was detected via Western blotting as described under
“Experimental Procedures.” Lane 1, biotin-labeled FN marker; lanes 2, 4, and 6, samples from the cells seeded on FNmatrices; lanes 3, 5, and 7, samples col-
lected from cells plated on TG-FN matrices. The histogram shows representative data (n 2) of the densitometric values obtained from the bands when
normalized using the densitometric values of the -tubulin bands. D, deposition of fibronectin is independent of TG2 cross-linking. A monolayer of WT MEF
cells was incubated with 500 M TG2 inhibitor R283 or DMSO (0.1%) in the presence of biotin-labeled FN for 6 or 16 h, respectively. Biotinylated FN fibril
staining was as described above.
TG-FN in Syndecan and Integrin Co-signaling and FNDeposition
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a modified ELISA (7) was performed to detect the TG2 matrix
after seeding the cells onto the TG-FN matrix for 16 h. Fig. 2C
demonstrates that the TG2 remained in the matrix and was
available to antibody binding after incubation with the cells
for 16 h, suggesting that the matrix-bound TG2 is able to sus-
tain a long term effect of the TG-FN complex on both cell
adhesion and FN deposition.
To test our hypothesis for the involvement of syndecan-4 in
FN fibril formation, we investigated FN fibril formation in
fibroblasts seeded on FN or TG-FN matrices using synde-
can-4 knock-out (KO) MEF, Y188L mutant MEF (syndecan-4
KO cells transfected with syndecan-4 cDNA mutated at the
PKC binding site), and GK21 peptide-treated MEF cells
(previously shown to block the interaction between PKC and
1 integrin at the cytoplasmic domain) (21). As shown in Fig.
3A, in these different cells where syndecan-4 function has
either been knocked out or altered, leading to reduced cell
attachment and spreading (22), no well organized FN fibrils
FIGURE 2.Deposition of cellular fibronectin by the TG-FN complex in an RGD-independent manner and detection of matrix-bound TG2. A, deposi-
tion of cellular FN was detected by an ELISA assay. The cells (at a density of 5 103, 1 104, or 2 104 cells/well) were allowed to adhere on FN or TG-FN
matrix in the presence of RGD or RAD peptides for 3 h and then detached with 5 mM EDTA in PBS, pH 7.4. The deposited cellular FN in the remaining matri-
ces was detected by ELISA using anti-mouse cellular FN antibody as described under “Experimental Procedures.” B, to visualize the cellular FN fibril forma-
tion, immunofluorescence staining was performed by using anti-mouse cellular FN and FITC-conjugated secondary antibodies after seeding the cells on FN
or TG-FN matrix in the presence of the RGD or RAD peptides for 3 h. The nuclei were detected with propidium iodide, and confocal microscopy was per-
formed to detect the signals as described under “Experimental Procedures.” Bar, 20 m. C, the presence of matrix TG2 after incubating the cells (at a density
of 5 103, 1 104, or 2 104 cells/well) with the FN or TG-FN matrix complex was detected via a modified ELISA by using anti-TG2 antibody Cub7402 after
seeding the cells for 16 h. CNTL, control.
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were observed. Moreover, this loss of FN fibril formation
could not be restored when cells were seeded on the TG-FN
complex and compared with wild type cells. This indicates for
the first time that syndecan-4 is involved in FN fibril assembly
particularly in the early stages following cell spreading, and
this function requires its downstream signaling effector mole-
cule PKC to mediate this process when cells are adhered to
TG-FN.
Our next objective was to distinguish the role of matrix-
bound TG2 from its proposed role as a cell surface integrin
co-receptor for fibronectin, which has also been shown to
enhance fibronectin fibril formation but in an integrin-depen-
dent manner. To do this, we stably transfected TG2 cDNA
into wild type MEF cells to establish the tg2-MEF cell line,
which expresses high levels of TG2 at the cell surface. As
shown in supplemental Fig. 1A, no detectable cell surface or
total TG2 antigen was found in wild type MEF cells, whereas
high levels were detectable in tg2-MEF cells. Despite the in-
creased cell surface enzyme expression of TG2 in these cells,
they did not support cell adhesion and spreading in the pres-
ence of RGD peptides on a FN matrix and showed no advan-
tages in this respect over wild type MEF cells (Fig. 3B) during
a 20–40-min incubation time. Only in the presence of a pre-
deposited TG-FN complex could the TG2-overexpressing
cells rescue the effect of the RGD peptides, with no significant
differences (p 0.05) observed between wild type and tg2-
MEF cells. This clearly suggests that cell surface TG2 is inca-
pable of mediating the RGD-independent cell adhesion and
confirms that its proposed role as a cell surface integrin-de-
pendent co-receptor for fibronectin is different from that
when it is bound to matrix fibronectin in mediating both cell
adhesion and fibronectin assembly (22).
The Direct Interaction between the Heparan Sulfates of Syn-
decan-4 and TG2 Is Important for TG-FN to Regulate Cell
Adhesion in the Presence of RGD Peptides—We previously
showed that even when the heparin binding site within FN is
blocked, TG-FN can still compensate for the loss of RGD-
induced cell adhesion, suggesting that TG2 is the functional
component in the TG-FN heterocomplex (22). As a continua-
tion of this study, we next used heparin, a high affinity bind-
ing partner for TG2 (31), to treat the already assembled
TG-FN complex to mask the potential heparin binding site(s)
within TG2 itself. As shown in Fig. 3C, heparin treatment
completely blocked the compensation of TG-FN in RGD-
induced loss of cell adhesion, further proving that the hepa-
rin-binding site(s) within TG2 is the functional component
for this TG-FN heterocomplex to exert its effect.
It has been reported that the core protein of syndecan-4
can also mediate cell spreading (36). Although our previous
data using heparinase treatment to digest cell surface heparan
sulfate chains and the use of heparan sulfate-deficient CHO
cells in cell adhesion studies (22) demonstrated the impor-
tance of cell surface heparan sulfates, the potential involve-
ment of the core protein of syndecan-4 in this process was not
ruled out. We therefore performed co-immunoprecipitation
assays using the CHO-K1 cells and the heparan sulfate mu-
tant CHO cells (devoid of cell surface heparan sulfates but
containing the syndecan-4 core protein) (36). Anti-synde-
can-4 antibody was used to pull down the syndecan-4-associ-
ated complex, and anti-TG2 antibody was used to detect the
presence of TG2 antigen within this complex using Western
blotting. As shown in Fig. 3D, unlike in the wild type cells, no
TG2 was detected in the heparan sulfate mutant cells, indicat-
ing that no direct interaction between TG2 and the core pro-
tein of syndecan-4 takes place during the RGD-independent
cell adhesion process mediated by TG2 when bound to FN.
51 Integrin Is Required for TG-FN to Exert Its Function in
Regulating RGD-independent Cell Adhesion and FN Fibril
Formation—Our previous work demonstrated that 1 inte-
grins are required for TG-FN to mediate its intracellular sig-
naling pathway that facilitates RGD-independent cell adhe-
sion. Further experiments were therefore undertaken in MEF
cells to investigate the role of the 1 integrin signaling path-
way and also the importance of the major FN binding com-
panion of 1, 5, in the RGD-independent cell adhesion pro-
cess on TG-FN.
Treatment of MEF cells with the 1 integrin functional
blocking antibody, HM1-1 (37), led to a 54% decrease in cell
attachment and blocked 57% of cell spreading on FN when
compared with non-treated cells seeded on FN. The isotype
control antibody did not show any effect on either cell adhe-
sion or spreading. In contrast, when cells seeded on TG-FN
matrix were treated with the function-blocking antibody, very
little loss (10%) of cell attachment and spreading was ob-
served (Fig. 4A). HM1-1 is thought to exert its blocking ef-
fect by inhibiting the signaling transduction of the 1 integrin
outside-in pathway (37), which can be confirmed via detect-
ing the phosphorylation of FAK, a downstream signaling mol-
ecule of 1 integrin. As shown in Fig. 4B, in HM1-1-treated
MEF cells, the antibody inhibited the phosphorylation of FAK
at Tyr397 in the cells seeded on FN matrix but not in the
TG-FN group, whereas the phosphorylation of Tyr861 (sug-
gestive of inside-out signaling) was not significantly affected
in both FN and TG-FN groups. Previously, we demonstrated
that TG-FN can compensate the phosphorylation of both
Tyr397 and Tyr861 in the RGD peptide-treated cells, suggest-
ing the requirement of FAK by TG-FN to exert its function
(21). Merging the discoveries together, we now show that the
signaling pathway mediated by 1 integrin in TG-FN-medi-
ated cell adhesion is that of inside-out signal transduction
FIGURE 3. TG2 is the functional component within the TG-FN complex and directly interacts with heparan sulfates of syndecan-4. A, after incubation
with biotin-labeled FN for 6 h, biotinylated FN fibril formation produced by WT, syndecan-4 KO, Y188L syndecan-4 mutant (Y188L), and GK21 peptide-
treated wild type MEF cells (GK21-wt) was detected as described under “Experimental Procedures.” Bar, 20 m. B, cell adhesion of WT MEF (wt MEF) and tg2-
MEF to FN and TG-FN matrices in the presence of 100 g/ml RAD or RGD peptide was undertaken as described under “Experimental Procedures.” The non-
treated cells were used as the control group (CNTL). C, heparin (300 g/ml) was applied after the formation of the TG-FN complex, and cell adhesion was
observed on non-treated and heparin-treated-TG-FN matrices. The percentages for cell attachment and spreading on non-treated FNmatrix in the pres-
ence of RAD peptide were set as 100%. D, co-immunoprecipitation of syndecan-4 and TG2 was performed by using wild type (wt) and heparan sulfate mu-
tant (hs-m) CHO cells, as described under “Experimental Procedures.” gplTG was used as the internal standard.
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because the phosphorylation at Tyr861 was not influenced by
the HM1-1 antibody (38).
The role of 5 integrin in association with 1 in FN-depen-
dent cell adhesion is well documented. Our hypothesis that
5 integrin is also the major companion of 1 integrin in me-
diating RGD-independent cell adhesion on TG-FN was first
tested by using 5 integrin knock-out EA5 embryo cells and
control EA5/5 cells (EA5 transfected back with 5 integrin)
(supplemental Fig. 1B) (15). Without 5 integrin, the EA5
cells adhered poorly compared with the control cells, and the
adhesive response of the knock-out cells was much more sus-
ceptible to RGD peptide than that of its control cells (Fig. 4C).
As expected, TG-FN failed to restore the loss of cell attach-
ment and spreading caused by the presence of RGD peptides.
To further confirm our observations for 51 involvement,
an inhibiting peptide, A1-5, was used in MEF cell adhesion
experiments. The peptide A5-1, which inhibits cell adhesion
and proliferation via its specific blocking and interaction with
51 integrin (33), inhibited cell attachment and spreading in
a dose-dependent manner, and at a concentration of 10 M, it
blocked cell attachment and spreading by50%. Importantly,
use of the peptide A5-1 led to the failure of the TG-FN het-
erocomplex to restore RGD-independent cell adhesion, con-
firming the importance of the 51 integrin in this process
(Fig. 4D).
To confirm the involvement of these integrin members in
FN fibril formation on TG-FN in the presence of RGD pep-
tide, we used 5 and 1 integrin null cells, respectively. As
expected, given the poor cell adhesion properties of these
cells, even after a 16-h incubation, the ability of these cells to
form fibronectin fibrils without either of these two cell sur-
face receptors was negligible (Fig. 4E). Importantly, even
those cells that did adhere did not form well organized fibrils
that could not be compensated for by plating the cells on the
TG-FN complex.
Syndecan-2 Is the Novel Cell Mediator in FN Fibril Forma-
tion When Cells Are Plated on TG-FN in the Presence of RGD
Peptides—As a further member of the syndecan family, synde-
can-2 is expressed in fibroblasts and has been shown to be
involved in actin cytoskeleton formation when cells are
seeded on fibronectin. We therefore hypothesized that synde-
can-2 might also be involved in the syndecan-4-mediated
RGD-independent cell adhesion on TG-FN and, given its im-
portance in actin cytoskeletal formation, may also be key to
the ability of TG-FN to mediate RGD-independent fibronec-
tin fibril formation.
Syndecan-2 involvement was first investigated by using
syndecan-2 siRNA-treated MEF cells in cell adhesion assays.
As shown in Fig. 5A, the syndecan-2 siRNA treatment signifi-
cantly reduced the expression of syndecan-2 to around 50%
compared with non-treated and the different control siRNA
groups. Importantly, the expression of both syndecan-4 and
1 integrin was not significantly affected. Fig. 5B shows the
inhibition of the siRNA in syndecan-2 expression in MEF cells
by immunofluorescence staining of syndecan-2. This indi-
cated that there was a fairly even knocking down effect on the
expression of syndecan-2 in the different MEF cells by the
specific targeting siRNAs. The syndecan-2 siRNA treatment
led to an25% loss of cell attachment and60% loss of cell
spreading on FN and a further 30% reduction of cell attach-
ment and 20%reduction in cell spreading in the presence of
RGD peptide. Importantly, TG-FN failed to compensate for
the effect of the RGD peptide on cell attachment and spread-
ing, indicating the requirement of syndecan-2 in the TG-FN
adhesion mechanism (Fig. 5C).
Fluorescent visualization of the actin stress fibers by confo-
cal microscopy indicated that syndecan-2 siRNA-treated MEF
cells could not form well organized actin cytoskeleton struc-
tures compared with the cells treated with the negative non-
silencing siRNA when plated on FN, confirming the impor-
tance of syndecan-2 in the formation of the actin
cytoskeleton. Moreover, the TG-FN complex can only rescue
the effect of the RGD peptide inhibition on actin stress fiber
formation in the MEF cells treated with the non-silencing
siRNA and not in the syndecan-2 siRNA-treated MEF cells
(Fig. 5D).
Next we confirmed the importance of syndecan-2 in medi-
ating fibronectin fibril formation in cells plated on TG-FN in
the presence of the RGD peptides. In keeping with the ability
of the syndecan-2-targeted siRNA to inhibit both cell spread-
ing and actin cytoskeleton formation (Fig. 5, C and D), FN
fibril formation was also found to be significantly reduced
when both visualized (Fig. 6A) and measured using Western
blotting (Fig. 6B). As shown in Fig. 6, A and B, the siRNA2
treatment resulted in around 50% reduction of FN deposition
in the cells seeded on both FN matrix and TG-FN groups us-
ing Western blotting and normalized per cell using -tubulin,
a figure that equates well with the siRNA knockdown of syn-
decan-2 in these cells (Fig. 5A). Hence, not only are there
fewer cells adhered after siRNA treatment (Fig. 5C), but those
cells remaining are also less efficient in fibril formation, which
probably accounts for the increased reduction in fibril forma-
tion visualized in Fig. 6A.
The above data suggested that syndecan-2 is the predomi-
nant cell surface receptor that can bind and mediate FN fibril
formation on TG-FN matrix in the presence of RGD peptide
FIGURE 4. The importance of 51 integrin in RGD-independent cell adhesion and FN fibril formationmediated by TG-FN. A, pretreated MEF cell
suspensions (2.5 105/ml) with 25 g/ml HM1-1 1 integrin functional blocking antibody or its isotype control antibody (CNTL) were seeded on FN or
TG-FN matrix with RAD or RGD peptide as described under “Experimental Procedures.” B, MEF cells treated as above were seeded on FN and TG-FN. The
presence of FAK-Y397 and FAK-Y861 was detected via Western blotting. -Tubulin was used to ensure equal loading. C, EA5 (5 integrin knock-out embryo
cells) and EA5/5 (EA5 cells transfected with human 5 integrin cDNA) were used in the TG-FN cell adhesion assay. Mean cell attachment and spreading are
expressed as a percentage of control values of non-treated EA5/5 cells on FN (which represents 100%) S.D. D, MEF cells were pretreated with various
concentrations of 51 integrin-targeted peptide A5-1 for 30 min, and cell adhesion was performed, whereas RAD and RGD peptides were used as controls.
Mean cell attachment and spreading are expressed as the percentage of control values of non-treated MEF cells on FN (which represents 100%) S.D. in
the presence of RAD peptide. E, TG-FN does not compensate for the loss of FN deposition caused by the absence of 5 and 1 integrin. Following a 16-h
incubation, biotinylated FN fibril formation by 5 (EA5) or 1 integrin null cells (1 INT ko) seeded on FN or TG-FN matrix was detected via fluorescence
staining. Bar, 20 m.
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because RGD peptides block the integrins and matrix TG2
keeps syndecan-4 occupied via their direct interactions. Thus,
the blocking of syndecan-2 should further affect the FN depo-
sition by the cells seeded on TG-FN matrix in the presence of
RGD peptide. To test the theory, heparin was used to block
the available cell surface heparan sulfates during the incuba-
FIGURE 5. The role of syndecan-2 in regulating RGD-independent cell adhesion on TG-FN. A, WT MEF cells were treated with specific syndecan-2-tar-
geting siRNAs (siRNA1 or -2), whereas the scrambled siRNAs (scr-siRNA1 and -2) and the negative non-silencing siRNA were used as the control treatments.
After incubation with siRNAs for 30 h, the samples were collected in cell lysis buffer to detect the presence of syndecan-2 via Western blotting by using anti-
syndecan-2 antibody. The membranes were stripped and reprobed with anti-syndecan-4 or 1 integrin antibody, whereas tubulin was used as the equal
loading standard. B, to visualize the presence of syndecan-2 in the syndecan-2 siRNA-treated MEF cells, the treated cells were seeded into 8-well chambers
and incubated with anti-syndecan-2 antibody (recognizing the intracellular domain of the syndecan-2 core protein) and anti-rabbit secondary antibody
after fixation and permeabilization as described under “Experimental Procedures.” The nuclei were detected with propidium iodide, and the signals were
detected via confocal microscopy. Bar, 20 m. C, MEF cell monolayers were treated with syndecan-2 siRNAs and control siRNAs as described under “Experi-
mental Procedures.” Cells were then seeded on either FN or TG-FN with 100 g/ml RGD (G) or RAD (A) synthetic peptide. The mean percentage value of
non-treated attached and spread cells on FN in the presence of RAD S.D. (error bars) (control) was used as 100%. D, actin stress fiber formation was de-
tected in syndecan-2 siRNAs (SDC-2 siRNAs) or control siRNA-treated (non-silencing (NS) siRNA) MEF cells with RAD or RGD peptide. Actin stress fibers were
stained by using FITC-labeled phalloidin. Bar, 20 m.
FIGURE 6. Syndecan-2 is required by TG-FN in mediating FN fibril formation. A, the syndecan-2 siRNAs (siRNA1 and siRNA2) and the negative control
siRNA-treated (NS siRNA) MEF monolayer cells were incubated with biotin-labeled FN for 6 h in the presence of RAD or RGD peptides, and fluorescence was
staining performed as described above. B, Western blotting was used to detect the biotin-labeled FN from the syndecan-2 siRNA2-treated MEF cells as de-
scribed under “Experimental Procedures.” Lane 1, biotin-labeled FN marker; lanes 2 and 3, cell lysates from the negative control siRNA-treated cells seeded
on FN or TG-FN matrix, respectively; lane 4, the sample from syndecan-2 siRNA2-treated cells plated on FN or TG-FN (lane 5). The histogram shows repre-
sentative densitometric values (n 2) obtained from the bands when normalized using the densitometric values of the -tubulin bands. C, FN fibril forma-
tion on TG-FN can be blocked by heparin. After adhering to the TG-FN matrix for 1 h to form the cell monolayer, the RGD or RAD peptide-treated MEF cells
were incubated with biotin-labeled FN with or without the presence or absence of 1 mg/ml heparin (to block the cell surface heparan sulfates). Cy5-conju-
gated streptavidin was used to detect the FN, and the signals were detected via confocal microscopy. Bar, 20 m.
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tion of biotin-labeled FN. As shown in Fig. 6C, as expected,
the presence of heparin completely blocked the FN fibril for-
mation when cells were seeded on FN-TG in the presence of
RGD peptide (35) after a 3-h incubation with the cells.
In order to further investigate the role of syndecan-2 in this
signaling pathway of TG-FN, we used immunoprecipitation
assays to detect the direct interaction of syndecan-2 with TG2
in the initial cell adhesion event. Unlike cell surface synde-
can-4, we could not demonstrate any direct interaction with
syndecan-2, confirming that syndecan-2 is acting downstream
of syndecan-4 (Fig. 7A). Given this downstream effector role
for syndecan-2 in cell adhesion and fibronectin fibril forma-
tion mediated by the TG-FN heterocomplex, we further ex-
plored whether the cross-talk between syndecan-4 and -2 was
mediated by PKC. Immunoprecipitation assays were per-
formed by using the anti-syndecan-2 antibody to pull down
the syndecan-2-associated proteins in wild type, syndecan-4
null cells and syndecan-4 mutant MEF cells (mutant Y118L,
without the PKC binding site in the syndecan-4 cytoplasmic
domain). As shown in Fig. 7B, by using a specific anti-PKC
antibody in Western blotting, the presence of this antigen was
detected in all three cell types, whereas interestingly, as might
be expected without the binding between PKC and synde-
can-4 mutant cell) or the presence of syndecan-4 (null cells),
the interaction between PKC and syndecan-2 was signifi-
cantly decreased.
Because it has been reported that Rho and ROCK are the
downstream signaling molecules in the syndecan-2 signaling
pathway (32), cell adhesion assays were further performed in
MEF cells by using the ROCK inhibitor Y27632, previously
shown to block the syndecan-2-mediated cell spreading and
focal adhesion formation in cells seeded on FN matrix (32).
As shown in Fig. 5C, the treatment of cells with Y27632 inhib-
ited more than 30% (p 0.05) cell attachment and spreading
on FN, compared with the control cells treated with DMSO.
Unlike the observed compensatory effect on the control cells,
TG-FN did not rescue the loss of cell attachment and spread-
ing in the Y27632-treated MEF cells (Fig. 7C), thus confirm-
ing the importance of ROCK.
Overexpression of either Syndecan-2 or Syndecan-4 Can
Enhance the Compensatory Effect of TG-FN in the RGD-inde-
pendent Cell Adhesion—To further confirm the wider impor-
tance of both syndecan-2 and 4 in FN-TG-mediated RGD-
independent cell adhesion, investigations were also
undertaken in transfected human glioblastoma cells T98G
overexpressing either syndecan-2 or syndecan-4 (29). TG-FN
compensated for the effect of RGD peptide and restored the
cell adhesion and spreading back to the levels in RAD pep-
tide-treated cells on FN in wild type T98G cells. The study
was further performed using glioblastoma cells overexpress-
ing syndecan-2 or syndecan-4 (29) (Fig. 8, A and C, respec-
tively). In the FN control groups, overexpressed syndecan-2
or syndecan-4 did not support any increased cell attachment
and spreading in the presence of RGD peptide, suggesting the
associated roles of these receptors in 1 integrin-mediated
cell adhesion. However, when seeded on TG-FN, over 30%
more cell attachment and around 40% more cell spreading
were achieved in both syndecan-2- and syndecan-4-overex-
pressing T98G cells in the RGD peptide-treated cells (Fig. 8, B
and D, respectively).
FIGURE 7. Syndecan-2 does not interact with TG2 directly but requires activation by PKC and can be blocked by ROCK inhibitor. A, co-immunopre-
cipitation of syndecan-2 and TG2 was performed as described under “Experimental Procedures,” whereas syndecan-4 antibody was used as the positive
control antibody for the pull-down procedure. gplTG was loaded as the internal standard. B, co-immunoprecipitation of PKC and syndecan-2 using synde-
can-2 antibody and detection of PKC by Western blotting. Samples from wild type (wt), syndecan-4 Y188L mutant (Y188L), and syndecan-4 null (SDC-4 ko)
MEF cells were prepared as described under “Experimental Procedures.” C, after treatment with ROCK inhibitor Y27632 (10 mM) or DMSO treatment (0.1%),
MEF cells were seeded on FN or TG-FN with RAD or RGD peptide. The percentage value of non-treated attached and spread cells on FN was used as 100%.
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TG-FN-mediated Cell Adhesion in the Presence of RGD Pep-
tides Does Not Depend on either 4 Integrin- or 3 Integrin-
activated Pathways—Because TG2 is also known to be a li-
gand for 41 integrin (39), which has been reported to be
expressed in mouse fibroblasts (40), we explored whether the
RGD-independent cell adhesion in response to TG-FN in-
volves 41 integrins in fibroblasts (41). The cell attachment
and spreading of MEF cells on FN and/or TG-FN was not
significantly (p 0.05) affected with either control mouse IgG
treatment or function-blocking anti-integrin 4 antibody
9C10 (42) treatments at 30 g/ml (Fig. 9A) in the presence of
RAD peptide. This antibody did not induce further loss of cell
attachment and spreading caused by the addition of RGD
peptides, agreeing with previous reports that this integrin
seems to only affect cell adhesion after incubation times lon-
ger than those used here (42). In both mouse IgG- and 9C10
antibody-treated cells, TG-FN rescued significantly the loss of
cell adhesion mediate by RGD peptides, suggesting that the
compensatory effect of this complex is independent of the
presence of cell surface 41 integrins.
Because of its reported involvement with TG2 (43), another
cell surface integrin, 3 integrin was also studied in RGD-
independent cell adhesion mediated by the TG-FN hetero-
complex (supplemental Fig. 1C). The absence of 3 integrins
FIGURE 8.Overexpression of syndecan-2 or syndecan-4 further enhances the compensatory effect of TG-FN complex. A and C, Western blotting of
syndecan-2 or syndecan-4 in wild type and syndecan-2- or syndecan-4-overexpressing T98G glioblastoma cells. Following cell surface biotinylation as de-
scribed under “Experimental Procedures,” -tubulin is used to control for equal loading of proteins. B and D, cell adhesion assay for syndecan-2 (SDC-2
T98G) or syndecan-4 T98G (SDC-4 T98G) cells was undertaken in the presence of RAD or RGD peptide. Mean cell attachment and spreading are expressed as
the percentage of control values of wild type T98G (wt T98G) or FN (which represents 100%) S.D. in the presence of RAD peptide.
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in 3 null MEF cells (Fig. 9B) did not affect cell attachment
significantly (p 0.05) compared with the wild type cells,
whereas the influence of this integrin on cell spreading was
very apparent in control and RAD groups seeded on FN ma-
trix. Without the presence of 3 integrins, the cell lost20%
of cell spreading. Importantly, the loss of 3 integrins did not
influence the effect of the TG-FN heterocomplex in compen-
sating for RGD peptide-induced loss of cell attachment and
spreading.
DISCUSSION
TG2 is now recognized as a wound response enzyme,
which, under stress conditions, is up-regulated, leading to its
secretion into the extracellular matrix (23, 24). In TG2 KO
animals, wound healing is delayed (23), whereas overexpres-
sion of the enzyme can lead to fibrosis (44). Once secreted
into the extracellular matrix, TG2 forms a heterocomplex
with its high affinity binding partner FN, which is thought to
mediate down-regulation of its transamidating activity and
make it more resistant to proteolytic degradation (7). We pre-
viously reported that this TG-FN complex could by virtue of
its binding to syndecan-4 and by activation of 1 integrin co-
signaling maintain cell adhesion and facilitate cell survival in
the presence of the RGD-containing peptides released during
matrix turnover. Interestingly, like TG2, syndecan-4 KO mice
also show delayed wound healing (45). In this paper, we ex-
tend our previous work first by investigating the role of this
RGD-independent cell adhesion process on fibronectin fibril
formation, an event key to wound healing; second, we also
explore the involvement of other cell surface receptor(s) and
signaling pathway(s) that are central to this event. Cell surface
TG2 involvement in fibronectin deposition in an integrin-de-
pendent but transamidating-independent manner has been
reported previously (46). In contrast, in other reports (47, 48),
the cross-linking activity of TG2 was also reported to be re-
quired in FN assembly and deposition. We therefore first
ruled out that the mechanism used by fibronectin matrix-
bound TG2 for both cell adhesion and FN fibril formation was
different from that used by cell surface TG2 (46) by demon-
strating that MEF cells overexpressing cell surface TG2 were
unable to compensate for RGD-mediated loss of cell adhe-
sion. By monitoring FN fibril formation through the addition
of soluble biotinylated FN, we also ruled out the involvement
of TG2 transamidating activity in this event because the addi-
tion of a site-directed TG irreversible inhibitor R283 had no
effect on the process. We show that the TG-FN complex can
increase the rate of fibril formation by wild type MEF cells
when compared with equal numbers of cells adhered on FN
alone in the early stages of FN deposition (1–6 h). Impor-
FIGURE 9. The roles of 41 and 3 integrins in cell adhesion on TG-FN. A, MEF cells in suspension (2.5 105) were pretreated with 30 g/ml anti-4
integrin antibody (9C10) or control mouse IgGs (isotype Ab) with RGD or RAD (100 g/ml) peptides before seeding on either FN or TG-FN. B, 3 integrin
wild type (wt MEF) and null (3 ko MEF) MEF cells were used in a cell adhesion experiment in the presence of RAD or RGD peptide. The mean cell attach-
ment and spreading values are expressed as the percentage of control values of non-treated wild type MEF on FN (which represents 100%) S.D.
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tantly, in keeping with the role of this stress-induced hetero-
complex in wound healing and matrix turnover, we demon-
strate that even in the presence of the RGD-containing
peptides, FN fibril formation was still maintained. This was in
direct contrast to cells seeded on FN alone, where the RGD
peptide treatment led to rounded cells with a lack of focal
adhesion assembly and a marked inhibition of FN fibril as-
sembly. This fits with previous observations in that focal ad-
hesion point assembly, actin cytoskeleton formation, and in-
tracellular signaling via RhoA are required for FN fibril
formation to occur (16), all of which are present in cells
seeded on TG-FN in the presence of RGD peptides.
Interestingly, it has been reported in longer term incuba-
tions (20 h) that no difference in FN fibril formation was ob-
served between syndecan-4 siRNA-treated cells and control
cells (15). Given our hypothesis that syndecan-4 may be im-
portant in the early stages of fibril formation following cell
spreading, we further investigated fibril formation in synde-
can-4 KO cells, the syndecan-4 Y188L mutant (which is un-
able to bind PKC), and cells treated with GK21 peptide
(which blocks binding of PKC to the cytoplasmic domain of
1 integrins (22)). The results of these experiments clearly
indicated that syndecan-4 and its downstream signaling mole-
cule PKC is required for FN bound TG2 to mediate FN fibril
formation. Given that there are two major sources of globular
FN present in any physiological system, the extracellular FN
from serum that is both in solution and surface-bound and
the cellular secreted FN from fibroblasts, we undertook to
investigate the effect of TG-FN matrix on cellular FN deposi-
tion. Our results confirmed that the FN-TG complex can also
deposit cellular FN in the presence of RGD peptide, indicating
that the two major sources of globular FN available to the cell
are deposited, not fibrillar, FN by this mechanism.
Our next step was to determine whether the TG2 bound to
the globular FN present on the original matrix remained de-
tectable and hence available to cells after FN fibril deposition
had occurred. To do this, the cells were removed by EDTA,
TG2 antibody was added to the remaining matrix, and the
immunocomplex was then detected by ELISA. Our data indi-
cated no change in the detectable levels of FN-bound TG2,
strongly suggesting the availability of this reservoir of TG2 to
the adherent cells for up to 16 h when RGD peptides are pres-
ent, thus confirming the ability of the TG-FN complex to
maintain cell spreading and facilitate FN fibril formation over
sustained periods of time.
Our next task was to determine which other cell surface
receptors were involved in TG-FN-induced cell adhesion in
the presence of RGD peptides and to assess their importance
in FN fibril formation. The important role of 1 integrin sig-
naling in regulating RGD-independent fibroblast cell adhe-
sion has been proven by our previous data (22). By using a 1
functional blocking antibody HM1-1, we confirmed that
TG-FN regulates signaling transduction through the inside-
out signaling pathway of 1 integrins because HM1-1 inhib-
ited cell adhesion on FN via blocking the phosphorylation of
FAK397, whereas with the phosphorylation of FAK861, the li-
gand-binding independent activation of FAK was maintained.
We then confirmed by using KO cells, specific inhibitory pep-
tides, and function blocking antibodies that 5 integrin, the
closest partner for 1 integrins, is involved in the RGD-inde-
pendent cell adhesion mediated by TG-FN, whereas the in-
volvement of other TG2-associating integrins, 41 and 3
integrins (39, 43), was ruled out. The poorly formed FN fibrils
by 1 or 5 integrin KO fibroblasts also confirmed that these
two receptors are required by TG-FN to enhance both cell
adhesion and FN fibril formation when fibroblasts are seeded
on it.
Syndecan-2 has been implicated as a downstream effector
in both 1 integrin and syndecan-4 signaling via facilitating
the formation of actin stress fiber formation (14). Because
RGD-dependent integrins are blocked by the presence of
RGD peptides and FN-bound TG2 is occupying heparan sul-
fate binding sites on syndecan-4, since we ruled out TG2
binding to the syndecan-2 core protein, other cell surface re-
ceptors would need to be involved to facilitate soluble FN
capture and fibril formation at the efficiency we observe. By
using syndecan-2 siRNA silencing, we first demonstrate a role
for this other important syndecan in the ability of TG-FN to
restore RGD-induced loss of cell adhesion. Importantly, by
using both siRNA silencing and the ROCK inhibitor Y27632,
we showed that syndecan-2 was key to formation of the actin
cytoskeleton and hence cell contraction, but unlike synde-
can-4, this role for syndecan-2 was independent of its binding
to TG2, leaving it free to bind to and assemble the biotinyl-
ated FN.
Indeed, when cells were seeded on TG-FN and treated with
heparin prior to and during FN assembly in the presence of
RGD peptide, it considerably reduced the amount of FN de-
posited, confirming the importance of the syndecan-2 in FN
deposition. Previous reports have demonstrated a role for
RGD-independent mechanisms involving heparan sulfate
proteoglycans in FN polymerization (35), and syndecan-2 has
been implicated as having a regulatory role in this mechanism
(49). The observation that siRNA silencing of syndecan-2
considerably reduced FN fibril formation when cells were
bound to FN-TG in the presence of RGD peptides strongly
suggests the importance of syndecan-2 in TG-FN-mediated
cell adhesion, cell contractility, and FN fibril formation.
Moreover, our data showed that 3 integrin is not required
for TG-FN-mediated cell adhesion, suggesting that the in-
volvement of 3 integrin, which can also assemble FN (50,
51), is not required in the RGD-independent mechanism of
FN fibril assembly mediated by the TG-FN heterocomplex.
Because phosphorylation of the V region of syndecan-2, like
that of syndecan-4, has been implicated in the role of synde-
can-2 (49) in regulating FN assembly, we investigated whether
PKC could be the potential link between syndecan-4 and
syndecan-2 as well as that between syndecan-4 and 51 in-
tegrin, thus facilitating both cell adhesion and FN fibril as-
sembly. Although it has been reported that syndecan-2 is in-
volved in the syndecan-4 signaling pathway, there has not
been any confirmed mechanism indicating how these two
receptors are linked. Regarding the fact that several members,
including PKC (52) and PKC (53), have been reported to be
involved in syndecan-2 signaling, we hypothesized that PKC
could be the potential link to connect these receptors. Our
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observation that PKC and syndecan-2 could be immunopre-
cipitated together and that this association was reduced in
syndecan-4 null cells and in syndecan-4 mutant Y188L cells
(without the PKC binding site in the syndecan-4 cytoplasmic
domain) seemed to confirm our hypothesis that PKC could
be the important link between these different syndecan recep-
tors. Moreover, the importance of both syndecan-2 and syn-
decan-4 in TG-FN-mediated cell adhesion in the presence of
RGD was confirmed using T98G glioblastoma cells overex-
pressing either syndecan-2 or syndecan-4 (29), which further
promoted the compensatory effect of TG-FN in an RGD-in-
dependent manner.
To conclude, our work demonstrates a number of impor-
tant cellular functions of TG2 not related to its cross-linking
activity when it is released into the extracellular matrix under
stress conditions such as those following tissue insult/injury.
Once bound to its high affinity binding partner FN, which is
also prevalent following tissue injury, it can maintain cell ad-
hesion and cell viability in the presence of RGD-containing
peptides released during matrix turnover. Importantly, while
maintaining cell adhesion and promoting cell spreading
through a PKC-mediated signaling cascade involving the
activation of syndecan-4, syndecan-2, and 51, the TG-FN
complex can also mediate FN fibril deposition (see Fig. 10), a
process that is central to a multitude of physiological and
pathological events.
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